Get notified when ORMP files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — Both Lifeward (49.99% equity stake, $13M+ in loans) and Scilex ($19.7M in outstanding notes) disclosed substantial doubt about ability to continue as going concern, creating concentrated credit and equity risk.
NASDAQ: ORMP ORAMED PHARMACEUTICALS INC. 10-K

revenue $2.0M, net income $64.0M. Oramed exits oral insulin, pivots to healthcare investments

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 27, 2025 · ~2 min read

Key Changes

  • high

    Sold entire POD oral insulin platform to Lifeward for up to 49.99% equity stake plus warrants and 4% ReWalk revenue share; R&D expenses now borne by Lifeward, not Oramed. Lifeward disclosed substantial doubt about ability to continue as going concern.

    Business: Lifeward transaction verify on EDGAR →
  • high

    Invested $38M in Alpha Tau (17% stake, oncology alpha-radiation therapy) and up to $18M in Nano Dimension (5% stake, activist posture); committed up to $40M to new VC fund Corner Ally Ventures focused on Israeli tech. Net income of $64M driven by $89M mark-to-market gains on these holdings.

    Business: Alpha Tau, Nano, Corner Ally; MD&A: Financial income verify on EDGAR →
  • high

    HTIT joint venture terminated October 2025 after partner failed to meet $60M+ funding commitments; Oramed instead sold OraTech to Lifeward. Planned Nasdaq listing and shareholder spin-off abandoned.

    Business: HTIT termination verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade ORMP commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify